Skip to main content
. 2015 Aug 1;8(8):9010–9020.

Figure 4.

Figure 4

COX-2 and p-EGFR expression in NSCLC cells treated with gefitinib, celecoxib, and gefitinib plus celecoxib. A549 and HCC827 cells were treated for 48 h with gefitinib (40 μmol/L), celecoxib (80 μmol/L), or gefitinib and celecoxib combined. There was significant COX-2 and p-EGFR downregulation both cell lines following treatment with gefitinib plus celecoxib compared to that following treatment with either drug alone.